Skip to main content
Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TERN ISIN · US8808811074 LEI · 254900S1ZDQMF4MYP709 US Professional, scientific and technical activities
Open in API
Filings indexed 406 across all filing types
Latest filing 2026-05-05 Share Issue/Capital Cha…
Country US United States of America
Listing US TERN

About Terns Pharmaceuticals, Inc.

https://ternspharma.com/

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops a portfolio of small-molecule product candidates for serious diseases, with a focus on oncology and obesity. The company's strategy is to innovate upon de-risked, clinically validated mechanisms of action to create therapies with superior efficacy, safety, and convenience profiles. Its lead product candidate, TERN-701, is an oral, allosteric BCR-ABL inhibitor in development for the treatment of chronic myeloid leukemia (CML). Terns aims to address significant unmet medical needs by improving upon existing treatments.

Recent filings

Filing Released Lang Actions
S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Share Issue/Capital Change Classification · 85% confidence The document is a Form S-8 Post-Effective Amendment filed with the SEC to deregister all unsold or unissued shares under various S-8 registration statements following a merger. It relates to the termination of offerings and removal of shares from registration, which constitutes a capital change. This fits the definition of a Share Issue/Capital Change announcement (SHA).
2026-05-05 English
S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Regulatory Filings Classification · 75% confidence The document is a post-effective amendment to Form S-8 filed with the SEC to deregister unsold securities. It is a regulatory compliance filing (Form S-8 amendment) with no earnings, financial statements, management discussion, or capital issuance beyond deregistration. It doesn’t fit the other specific categories (e.g., earnings release, interim report, share repurchase, M&A proxy, etc.), so it is best classified as a general regulatory filing (RNS).
2026-05-05 English
S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Regulatory Filings Classification · 85% confidence The document is a post‐effective amendment to Form S-8 registration statements, relating to the deregistration of unsold shares under the company’s equity plans. It is a regulatory SEC filing (Form S-8 Post-Effective Amendment) and contains no substantive financial statements or analysis; it is neither an earnings release nor an annual or interim report. It does not fall under share repurchase (POS) or standard share issuance announcements (SHA). Therefore, it is best classified as a general regulatory filing (RNS).
2026-05-05 English
S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Share Issue/Capital Change Classification · 85% confidence The document is a Form S-8 Post-Effective Amendment filed with the SEC to deregister all unsold shares under various employee equity plans following a merger. It effects a change in the company’s capital structure by removing registered but unissued shares from registration. This falls under the definition of a share/capital change announcement rather than an operational report or financial statements. Therefore, it is classified as Share Issue/Capital Change (SHA).
2026-05-05 English
S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form S-8 Post-Effective Amendment filed with the SEC to deregister unsold securities under various Form S-8 registration statements. It provides statutory and procedural information for compliance with the Securities Act of 1933 and does not include financial results, board changes, dividend details, or other specialized report content. It is effectively a miscellaneous SEC regulatory filing announcing the deregistration of shares. This falls under the catch-all Regulatory Filings category.
2026-05-05 English
S-8 POS - Terns Pharmaceuticals, Inc. (0001831363) (Filer)
Share Issue/Capital Change Classification · 87% confidence The document is a Form S-8 Post-Effective Amendment filed with the SEC to deregister unsold shares under existing registration statements, effectively a corporate capital change relating to share registration. This is not an operational report (like earnings or annual report), not a governance memo, and not a meeting announcement. It is an SEC regulatory filing covering a change in the company's registered share capital. Under our taxonomy, this falls under Share Issue/Capital Change (SHA).
2026-05-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.